647Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States

647. Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States Lindsay Kim, MD, MPH; Thomas H. TaylorJr., PE, MS; Tracy Pondo, MSPH; Monica M. Farley, MD; William Schaffner, MD; Arthur Reingold, MD; Ann Thomas, MD, MPH; Lee Harrison, MD MPH; Ruth Lynfield, MD; Nancy M. Bennett, MD; Susan Petit, MPH; Lisa Miller,; Megin Nichols, MD, MSPH; Lesley Mcgee, DVM, MPH, DACVPM; Bernard Beall, PhD; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA; Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Decatur, GA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; University of California Berkeley, Berkeley, CA; Oregon Public Health Division, Portland, OR; Johns Hopkins University, Baltimore, MD; Minnesota Department of Health, St. Paul, MN; University of Rochester Medical Center, Rochester, NY; Connecticut Department of Public Health, Hartford, CT; Colorado Department of Public Health and Environment, Denver, CO; New Mexico Department of Public Health, Santa Fe, NM